Showing 1131-1140 of 1583 results for "".
- Results of Phase 2 Study Demonstrate Safety and Efficacy of Galderma's Proprietary Liquid Toxinhttps://modernaesthetics.com/news/results-of-phase-2-study-demonstrate-safety-and-efficacy-of-galdermas-proprietary-liquid/2472827/Results of a Phase 2 study show Galderma’s novel liquid abotulinum toxin, QM1114, is safe and effective for the treatment of glabellar lines. Galderma is now poised to advance to Phase 3 testing of the liquid formulation of botulinum toxin type A for the treatment of glabellar lines. The tr
- BTL Gives Back Through New Dress for Success Partnershiphttps://modernaesthetics.com/news/btl-gives-back-through-new-dress-for-success-partnership/2471883/BTL is partnering with Dress for Success, a global not-for-profit organization that provides women with support, professional attire and development tools to help them reenter the work force. This partnership kicks-off a broader marketing effort by BTL – BTL Cares -- which provides
- Galderma Joins Forces with Three Charitieshttps://modernaesthetics.com/news/galderma-joins-forces-with-three-charities/2471904/Galderma is partnering with
- ASAPS: Americans Spent More than $2B on Silicone Gel Breast Implants and Injectables in 2018https://modernaesthetics.com/news/asaps-americans-spent-more-than-2b-on-silicone-gel-breast-implants-and-injectables-in-2018/2471919/Americans spent more than $2 billion on silicone gel breast implants and injectables in 2018 alone, according to new data from The American Society for Aesthetic Plastic Surgery (The Aesthetic Society). Breast
- Galderma's Dysport Celebrates 10 Years Since FDA Approvalhttps://modernaesthetics.com/news/dysport-celebrates-10-years-since-fda-approval/2471921/Galderma Laboratories’ Dysport (abobotulinumtoxinA) is ringing in its 10th birthday. To celebrate this milestone, Galderma is offering double points for Dysport aesthetic treatments registered in
- MedShift Reports Third Consecutive Year of Growthhttps://modernaesthetics.com/news/medshift-reports-third-consecutive-year-of-growth/2471950/MedShift has achieved its third consecutive year of 300% year-over-year growth and advancement of its patient-facing vConfidence and Effronte brands, according to
- FDA Clears Lutronic Genius Platform for RF Microneedlinghttps://modernaesthetics.com/news/fda-clears-lutronic-genius-platform-for-rf-microneedling/2471952/Lutronic has received FDA clearance of the Lutronic Genius™ platform for radiofrequency microneedling. The company says the device transmits energy more precisely into the skin. The Lutronic Intelligent Care™products incorp
- BD Unveils Prefillable Glass Syringe for Viscous Solutionshttps://modernaesthetics.com/news/bd-unveils-refillable-glass-syringe-for-viscous-solutions/2471953/BD (Becton, Dickinson and Company) has presented BD Hylok,its new glass pre-fillable syringe for the administration of viscous solutions such as hyaluronic acid dermal fillers, at Pharmapack 2019. BD Hylokis also the first glass pre-fillab
- Galderma Announces Formation of Women in Aesthetics Leadership Councilhttps://modernaesthetics.com/news/galderma-announces-formation-of-women-in-aesthetics-leadership-council/2471960/Galderma Laboratories, L.P. is forming a Women in Aesthetics Leadership Council. The newly formed Council is comprised of clinicians, clinical trial investigators, CEOs, business owners, and practice managers. "In most industries in the U.S. wome
- SENTE Launches Collaborations with Galderma, The HydraFacial Companyhttps://modernaesthetics.com/news/sente-launches-collaborations-with-galderma-the-hydrafacial-company/2471981/New strategic collaborations are intended to broaden the reach of SENTÉ and further expand their disruptive professional grade skin care product portfolio, the company says. Both collaborations will offer consumers the opportunity